Like many other companies, Dynavax Technologies Corporation (NASDAQ:DVAX) has embarked on a strategy to fight the COVID-19. The company is teaming up with Medicago to fast–track the development of a novel and adjuvanted vaccine candidate for the coronavirus. The two will bring together their advanced and plant-based technologies – CpG 1018 from Dynavax and Coronavirus Virus-Like Particle (CoVLP) from Medicago.
Medicago is already witnessing encouraging results from a Phase 1 clinical trial of an adult hepatitis B vaccine, approved by the FDA and which is likely to safeguard a greater number of people. Thus, the company is in anticipation of the approval of the COVID-19 Vaccine Candidate.
Positive Outcomes Will Reinforce the Capabilities of the Plant-Based Platforms
The world is desperate because of the overwhelming spread of the coronavirus. The fact that till now there is no endorsed vaccine makes the situation more despairing. However, biopharmaceutical companies are still hopeful that the situation can be reversed. Many of them have turned to collaborative approaches and partnerships.
According to President and CEO of Medicago, Dr. Bruce Clark, they are pleased with the positive outcomes from the company’s preclinical testing. They are encouraging, but they are also giving tangible hope of the vaccine being able to address this global public health threat.
“…We hope to maximize the number of doses we can produce with the objective to protect as many people as possible against COVID-19,” Clark said. Upon successful evaluation and approval, the two companies anticipate distributing more than 100 million doses of the vaccine by the end of 2021.
Dynavax Has Partnered With Several Other Players to Develop Other Treatments
The urgent need for the COVID-19 vaccine seems to have overshadowed many other activities across the globe. However, Dynavax is keen not to forget that hundreds of infectious diseases need to be addressed.
In this knowledge, the company partners with other key players in the market, including Valneva SE. The company with operations in France, Canada, Sweden, and Austria is so passionate about investigating, innovating, and improving vaccines that protect in unpredictable circumstances such as COVID-19.